

Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) patients

ID Study: FIL_COLUMN EudraCT number: 2021-000715-23

INVESTIGATOR SPONSOR: Fondazione Italiana Linfomi ONLUS (FIL)

Description

A Phase 2, multicenter, open-label, single-arm study of the efficacy and safety of loncastuximab tesirine given as consolidation therapy after a short course of immunochemotherapy in BTKi-treated (or BTKi intolerant) R/R MCL patients. R/R MCL after one, two or three lines of treatment including BTKi treatment (or BTKi intolerant), with complete (CR) or partial response (PR) or with stable disease (SD) after salvage therapy (R-BAC x 2) will undergo consolidation with loncastuximab tesirine. The primary endpoint will be assessed 12 months after the start of treatment of the last patient enrolled.

PUBLISHED MANUSCRIPTS (15)

[Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.](#)

Visco C, Di Rocco A, Evangelista A, Quaglia FM, Tisi MC, Morello L, Zilioli VR, Rusconi C, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Marin-Niebla A, McCulloch R, Gini G, Perrone T, Nassi L, Pennese E, Stefani PM, Cox MC, Bozzoli V, Fabbri A, Polli V, Ferrero S, Celis MIA, Sica A, Petrucci L, Arcaini L, Rule S, Krampera M, Vitolo U, Balzarotti M. *Leukemia*. 2021 Mar;35(3):787-795. doi: 10.1038/s41375-020-01013-3. Epub 2020 Aug 11. PMID: 32782382

[Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.](#)

McCulloch R, **Visco C**, Eyre TA, Frewin R, Phillips N, Tucker DL, Quaglia FM, McMillan A, Lambert J, Crosbie N, Rule S. *Br J Haematol*. 2020 May;189(4):684-688. doi: 10.1111/bjh.16416. Epub 2020 Feb 3. PMID: 32011729

[Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.](#)

Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, Evangelista A, Spina M, Molinari A, Rigacci L, Tani M, Rocco AD, Pinotti G, Fabbri A, Zambello R, Finotto S, Gotti M, Carella AM, Salvi F, Pileri SA, Ladetto M, Ciccone G, Gaidano G, Ruggeri M, Martelli M, Vitolo U. *Lancet Haematol*. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5. PMID: 27927586

[Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.](#)

Arcari A, Morello L, Vallisa D, Marcheselli L, Tecchio C, Quaglia FM, Tisi MC, Zilioli VR, Di Rocco A, Perrone T, Gini G, Dogliotti I, Bianchetti N, Bozzoli V, De Philippis C, Alvarez De Celis MI, Chiappella A, Fabbri A, Pelosini M, Merli M, Molinari AL, Sciarra R, Volpetti S, Hohaus S, Nassi L, **Visco C**. *Leuk Lymphoma*. 2021 Dec;62(14):3474-3483. doi: 10.1080/10428194.2021.1961238. Epub 2021 Oct 8. PMID: 34625013

[Rituximab and Bendamustine \(BR\) Compared with Rituximab, Bendamustine, and Cytarabine \(R-BAC\) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.](#)

Bega G, Olivieri J, Riva M, Scapinello G, Paolini R, Finotto S, Sartori R, Lucchini E, Guandalini G, Facchinelli D, Tisi MC, Basso M, Ballotta L, Piazza F, Ferrarini I, **Visco C**. *Cancers (Basel)*. 2021 Dec 3;13(23):6089. doi: 10.3390/cancers13236089. PMID: 34885198

[Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy.](#)

Marangon M, **Visco C**, Barbui AM, Chiappella A, Fabbri A, Ferrero S, Galimberti S, Luminari S, Musuraca G, Re A, Zilioli VR, Ladetto M. *Cancers (Basel)*. 2021 Jan 14;13(2):291. doi: 10.3390/cancers13020291

[Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.](#)

Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. *Br J Haematol*. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. PMID: 30407625

[A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi \(FIL\) MCL0208 Phase III Trial.](#)

Zaccaria GM, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, Drandi D, Ghislieri M, Barbero D, Del Giudice I, Tani M, Moia R, Volpetti S, Cabras MG, Di Renzo N, Merli F, Vallisa D, Spina M, Pascarella A, Latte G, Patti C, Fabbri A, Guarini A, Vitolo U, Hermine O, Kluin-Nelemans HC, Cortelazzo S, Dreyling M, Ladetto M. *Cancers (Basel)*. 2021 Dec 31;14(1):188. doi: 10.3390/cancers14010188. PMID: 35008361

[Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial.](#)

Genuardi E, Romano G, Beccuti M, Alessandria B, Mannina D, Califano C, Rota Scalabrini D, Cortelazzo S, Ladetto M, Ferrero S, Calogero RA, Cordero F. *Br J Haematol*. 2021 Jul;194(2):378-381. doi: 10.1111/bjh.17519. Epub 2021 May 18. PMID: 34002365

[Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi \(FIL\) multicentre, randomised, phase 3 trial.](#)

Ladetto M, Cortelazzo S, Ferrero S, Evangelista A, Mian M, Tavarozzi R, Zanni M, Cavallo F, Di Rocco A, Stefoni V, Pagani C, Re A, Chiappella A, Balzarotti M, Zilioli VR, Gomes da Silva M, Arcaini L, Molinari AL, Ballerini F, Ferreri AJM, Puccini B, Benedetti F, Stefani PM, Narni F, Casaroli I, Stelitano C, Ciccone G, Vitolo U, Martelli M. *Lancet Haematol*. 2021 Jan;8(1):e34-e44. doi: 10.1016/S2352-3026(20)30358-6. Epub 2020 Dec 22. PMID: 33357480

[Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network.](#)

Drandi D, Alcantara M, Benmaad I, Söhlbrandt A, Lhermitte L, Zaccaria G, Ferrante M, Genuardi E, Mantoan B, Villarese P, Cheminant M, Starza ID, Ciabatti E, Bomben R, Jimenez C, Callanan M, Abdo C, Eckert C, Ribrag V, Cortelazzo S, Dreyling M, Hermine O, Delfau-Larue MH, Pott C, Ladetto M, Ferrero S, Macintyre E. *Hemasphere*. 2020 Apr 3;4(2):e347. doi: 10.1097/HS9.0000000000000347. eCollection 2020 Apr. PMID: 32309784

[Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.](#)

Zaccaria GM, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, Sandrone R, Castagneri C, Barbero D, Lo Schirico M, Arcaini L, Molinari AL, Ballerini F, Ferreri A, Omedè P, Zamò A, Balestra G, Boccadoro M, Cortelazzo S, Ladetto M. *JCO Clin Cancer Inform*. 2019 Oct;3:1-15. doi: 10.1200/CCI.19.00049. PMID: 31633999

[KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study.](#)

Ferrero S, Rossi D, Rinaldi A, Bruscazzin A, Spina V, Eskelund CW, Evangelista A, Moia R, Kwee I, Dahl C, Di Rocco A, Stefoni V, Diop F, Favini C, Ghione P, Mahmoud AM, Schipani M, Kolstad A, Barbero D, Novero D, Paulli M, Zamò A, Jerkeman M, da Silva MG, Santoro A, Molinari A, Ferreri A, Grønbaek K, Piccin A, Cortelazzo S, Bertoni F, Ladetto M, Gaidano G. *Haematologica*. 2020 Jun;105(6):1604-1612. doi: 10.3324/haematol.2018.214056. Epub 2019 Sep 19. PMID: 31537689

[A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial.](#)

Bomben R, Ferrero S, D'Agaro T, Dal Bo M, Re A, Evangelista A, Carella AM, Zamò A, Vitolo U, Omedè P, Rusconi C, Arcaini L, Rigacci L, Luminari S, Piccin A, Liu D, Wiestner A, Gaidano G, Cortelazzo S, Ladetto M, Gattei V. *Haematologica*. 2018 May;103(5):849-856. doi: 10.3324/haematol.2017.184325. Epub 2018 Feb 22. PMID: 29472356

[Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.](#)

Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, Drandi D, Montechiarelo E, Ladetto M, Carmichael J, Fanin R. *Haematologica*. 2017 May;102(5):e203-e206. doi: 10.3324/haematol.2016.154211. Epub 2017 Jan 12. PMID: 28082342